open access

Vol 86, No 6 (2018)
ORIGINAL PAPERS
Published online: 2018-12-30
Submitted: 2018-09-10
Accepted: 2018-10-15
Get Citation

Factors predisposing to non-tuberculous mycobacterial lung disease in the patients with respiratory isolates of non-tuberculous mycobacteria.

Monika Szturmowicz, Izabela Siemion-Szcześniak, Dorota Wyrostkiewicz, Magdalena Klatt, Sylwia Brzezińska, Anna Zabost, Anna Lewandowska, Dorota Filipczak, Karina Oniszh, Agnieszka Skoczylas, Ewa Augustynowicz-Kopeć, Jan Kuś
DOI: 10.5603/ARM.a2018.0043
·
Pubmed: 30594992
·
Adv Respir Med 2018;86(6):261-267.

open access

Vol 86, No 6 (2018)
ORIGINAL PAPERS
Published online: 2018-12-30
Submitted: 2018-09-10
Accepted: 2018-10-15

Abstract

Introduction: An increasing incidence rate of respiratory isolates of non-tuberculous mycobacteria (NTM) has been noted recently
in most European countries as well as in the US. Despite many publications, there is no consensus concerning the importance of
different factors in promoting NTM lung disease (NTMLD).
The aim of the present retrospective study was to analyse patients with positive NTM respiratory isolates in search of factors
predisposing to NTMLD.


Material and methods: 73 patients, 23 males, 50 females, median age 62.2 years, in whom NTM have been cultured from
respiratory specimen (sputum and/or bronchial washings), in the period 2010–2015, entered the study.


Results: NTMLD (according to ATS/IDSA) has been recognised in 36 patients, airways colonisation by NTM — in 37 patients. NTMLD
was diagnosed more often in the patients infected with M. kansasii, M. abscessus and M. avium/M. intracellulare comparing to those
infected with M. xenopi, M. gordonae and M. fortuitum (p < 0.0001). The proportion of females to males was significantly higher in
the NTMLD group comparing to the colonisation group (p < 0.007). Previous tuberculosis or mycobacteriosis were noted significantly
more frequently in the group of patients with NTMLD comparing to the colonisation group (28% vs 8%, p = 0.038). Univariate regression
analysis revealed M. kansasii, female gender, and previous tuberculosis or mycobacteriosis as significant predictors of NTMLD.


Conclusions: The risk factors of NTMLD recognition in the presented group of patients were the following: female gender,
M. kansasii isolation, as well as past tuberculosis or mycobacteriosis.

Abstract

Introduction: An increasing incidence rate of respiratory isolates of non-tuberculous mycobacteria (NTM) has been noted recently
in most European countries as well as in the US. Despite many publications, there is no consensus concerning the importance of
different factors in promoting NTM lung disease (NTMLD).
The aim of the present retrospective study was to analyse patients with positive NTM respiratory isolates in search of factors
predisposing to NTMLD.


Material and methods: 73 patients, 23 males, 50 females, median age 62.2 years, in whom NTM have been cultured from
respiratory specimen (sputum and/or bronchial washings), in the period 2010–2015, entered the study.


Results: NTMLD (according to ATS/IDSA) has been recognised in 36 patients, airways colonisation by NTM — in 37 patients. NTMLD
was diagnosed more often in the patients infected with M. kansasii, M. abscessus and M. avium/M. intracellulare comparing to those
infected with M. xenopi, M. gordonae and M. fortuitum (p < 0.0001). The proportion of females to males was significantly higher in
the NTMLD group comparing to the colonisation group (p < 0.007). Previous tuberculosis or mycobacteriosis were noted significantly
more frequently in the group of patients with NTMLD comparing to the colonisation group (28% vs 8%, p = 0.038). Univariate regression
analysis revealed M. kansasii, female gender, and previous tuberculosis or mycobacteriosis as significant predictors of NTMLD.


Conclusions: The risk factors of NTMLD recognition in the presented group of patients were the following: female gender,
M. kansasii isolation, as well as past tuberculosis or mycobacteriosis.

Get Citation

Keywords

non-tuberculous mycobacteria, COPD, bronchiectasis, interstitial lung disease, corticosteroids

About this article
Title

Factors predisposing to non-tuberculous mycobacterial lung disease in the patients with respiratory isolates of non-tuberculous mycobacteria.

Journal

Advances in Respiratory Medicine

Issue

Vol 86, No 6 (2018)

Pages

261-267

Published online

2018-12-30

DOI

10.5603/ARM.a2018.0043

Pubmed

30594992

Bibliographic record

Adv Respir Med 2018;86(6):261-267.

Keywords

non-tuberculous mycobacteria
COPD
bronchiectasis
interstitial lung disease
corticosteroids

Authors

Monika Szturmowicz
Izabela Siemion-Szcześniak
Dorota Wyrostkiewicz
Magdalena Klatt
Sylwia Brzezińska
Anna Zabost
Anna Lewandowska
Dorota Filipczak
Karina Oniszh
Agnieszka Skoczylas
Ewa Augustynowicz-Kopeć
Jan Kuś

References (41)
  1. Honda JR, Alper S, Bai X, et al. Acquired and genetic host susceptibility factors and microbial pathogenic factors that predispose to nontuberculous mycobacterial infections. Curr Opin Immunol. 2018; 54: 66–73.
  2. Johnson MM, Odell JA. Nontuberculous mycobacterial pulmonary infections. J Thorac Dis. 2014; 6(3): 210–220.
  3. Field SK, Cowie RL. Lung disease due to the more common nontuberculous mycobacteria. Chest. 2006; 129(6): 1653–1672.
  4. Donohue MJ. Increasing nontuberculous mycobacteria reporting rates and species diversity identified in clinical laboratory reports. BMC Infect Dis. 2018; 18(1): 163.
  5. Shah NM, Davidson JA, Anderson LF, et al. Pulmonary Mycobacterium avium-intracellulare is the main driver of the rise in non-tuberculous mycobacteria incidence in England, Wales and Northern Ireland, 2007-2012. BMC Infect Dis. 2016; 16: 195.
  6. Adzic-Vukicevic T, Barac A, Blanka-Protic A, et al. Clinical features of infection caused by non-tuberculous mycobacteria: 7 years' experience. Infection. 2018; 46(3): 357–363.
  7. Prevots DR, Loddenkemper R, Sotgiu G, et al. Nontuberculous mycobacterial pulmonary disease: an increasing burden with substantial costs. Eur Respir J. 2017; 49(4).
  8. van Ingen J, Hoefsloot W, Dekhuijzen PNR, et al. The changing pattern of clinical Mycobacterium avium isolation in the Netherlands. Int J Tuberc Lung Dis. 2010; 14(9): 1176–1180.
  9. Hoefsloot W, van Ingen J, Andrejak C, et al. Nontuberculous Mycobacteria Network European Trials Group. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J. 2013; 42(6): 1604–1613.
  10. Stout JE, Koh WJ, Yew WW. Update on pulmonary disease due to non-tuberculous mycobacteria. Int J Infect Dis. 2016; 45: 123–134.
  11. Prevots DR, Shaw PA, Strickland D, et al. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med. 2010; 182(7): 970–976.
  12. Wilińska E, Oniszh K, Augustynowicz-Kopeć E, et al. Non-tuberculous mycobacterial lung disease (NT MLD ) in patients with chronic thromboembolic pulmonary hypertension and idiopathic pulmonary arterial hypertension. Pneumonol Alergol Pol. 2014; 82(6): 495–502.
  13. Griffith DE, Aksamit T, Brown-Elliott BA, et al. ATS Mycobacterial Diseases Subcommittee, American Thoracic Society, Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007; 175(4): 367–416.
  14. Haworth CS, Banks J, Capstick T, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax. 2017; 72(Suppl 2): ii1–ii64.
  15. Glassroth J. Pulmonary disease due to nontuberculous mycobacteria. Chest. 2008; 133(1): 243–251.
  16. R core team (2018). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https://www.R-project.org/.
  17. Winthrop KL, McNelley E, Kendall B, et al. Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease. Am J Respir Crit Care Med. 2010; 182(7): 977–982.
  18. Adjemian J, Olivier KN, Seitz AE, et al. Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med. 2012; 185(8): 881–886.
  19. van Ingen J, Bendien SA, de Lange WCM, et al. Clinical relevance of non-tuberculous mycobacteria isolated in the Nijmegen-Arnhem region, The Netherlands. Thorax. 2009; 64(6): 502–506.
  20. Kim RD, Greenberg DE, Ehrmantraut ME, et al. Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med. 2008; 178(10): 1066–1074.
  21. Bakuła Z, Kościuch J, Safianowska A, et al. Clinical, radiological and molecular features of Mycobacterium kansasii pulmonary disease. Respir Med. 2018; 139: 91–100.
  22. van Ingen J, Wagner D, Gallagher J, et al. NTM-NET. Poor adherence to management guidelines in nontuberculous mycobacterial pulmonary diseases. Eur Respir J. 2017; 49(2).
  23. Suzuki K, Kurashima A, Tatsuno K, et al. Clinical significance and epidemiologic analyses of Mycobacterium avium and Mycobacterium intracellulare lung disease from post-marketing surveillance. Respir Investig. 2018; 56(1): 87–93.
  24. Hoefsloot W, van Ingen J, Magis-Escurra C, et al. Prevalence of nontuberculous mycobacteria in COPD patients with exacerbations. J Infect. 2013; 66(6): 542–545.
  25. Char A, Hopkinson NS, Hansell DM, et al. Evidence of mycobacterial disease in COPD patients with lung volume reduction surgery; the importance of histological assessment of specimens: a cohort study. BMC Pulm Med. 2014; 14: 124.
  26. Andréjak C, Nielsen R, Thomsen VØ, et al. Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis. Thorax. 2013; 68(3): 256–262.
  27. Brode SK, Campitelli MA, Kwong JC, et al. The risk of mycobacterial infections associated with inhaled corticosteroid use. Eur Respir J. 2017; 50(3).
  28. Diel R, Jacob J, Lampenius N, et al. Burden of non-tuberculous mycobacterial pulmonary disease in Germany. Eur Respir J. 2017; 49(4).
  29. Hurst JR, Elborn JS, De Soyza A, et al. BRONCH-UK Consortium. COPD-bronchiectasis overlap syndrome. Eur Respir J. 2015; 45(2): 310–313.
  30. Gatheral T, Kumar N, Sansom B, et al. COPD-related bronchiectasis; independent impact on disease course and outcomes. COPD. 2014; 11(6): 605–614.
  31. Martínez-García MA, de la Rosa Carrillo D, Soler-Cataluña JJ, et al. Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013; 187(8): 823–831.
  32. Shteinberg M, Stein N, Adir Y, et al. Prevalence, risk factors and prognosis of nontuberculous mycobacterial infection among people with bronchiectasis: a population survey. Eur Respir J. 2018; 51(5).
  33. Henkle E, Aksamit TR, Barker AF, et al. Pharmacotherapy for Non-Cystic Fibrosis Bronchiectasis: Results From an NTM Info & Research Patient Survey and the Bronchiectasis and NTM Research Registry. Chest. 2017; 152(6): 1120–1127.
  34. Axson EL, Bloom CI, Quint JK. Nontuberculous mycobacterial disease managed within UK primary care, 2006-2016. Eur J Clin Microbiol Infect Dis. 2018; 37(9): 1795–1803.
  35. Ito Y, Hirai T, Fujita K, et al. Increasing patients with pulmonary Mycobacterium avium complex disease and associated underlying diseases in Japan. J Infect Chemother. 2015; 21(5): 352–356.
  36. Park SW, Song JW, Shim TS, et al. Mycobacterial pulmonary infections in patients with idiopathic pulmonary fibrosis. J Korean Med Sci. 2012; 27(8): 896–900.
  37. Brode SK, Jamieson FB, Ng R, et al. Increased risk of mycobacterial infections associated with anti-rheumatic medications. Thorax. 2015; 70(7): 677–682.
  38. Słupek A, Zwolska Z, Miller M, et al. [Pulmonary mycobacteriosis--diagnostic problem and prevalence in Poland (a retrospective study)]. Pneumonol Alergol Pol. 1997; 65(5-6): 326–332.
  39. Wyrostkiewicz D, Skorupa W, Jakubowska L, et al. [Mycobacterial lung disease in patients with cystic fibrosis--report of three cases]. Pneumonol Alergol Pol. 2014; 82(6): 561–567.
  40. Adjemian J, Olivier KN, Prevots DR. Epidemiology of Pulmonary Nontuberculous Mycobacterial Sputum Positivity in Patients with Cystic Fibrosis in the United States, 2010-2014. Ann Am Thorac Soc. 2018; 15(7): 817–826.
  41. Gardner AI, McClenaghan E, Saint G, et al. Epidemiology of nontuberculous mycobacteria infection in children and young people with cystic fibrosis: analysis of UK Cystic Fibrosis Registry. Clin Infect Dis. 2018 [Epub ahead of print].

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl